T2 Biosystems, Inc. (TTOO)
USD 0.35
(2.88%)
USD 0.35
(2.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -43.87 Million USD | 16.54% |
| 2022 | -55.19 Million USD | -30.05% |
| 2021 | -41.12 Million USD | -3.3% |
| 2020 | -38.48 Million USD | 20.06% |
| 2019 | -48.29 Million USD | -16.16% |
| 2018 | -41.95 Million USD | 12.08% |
| 2017 | -50.58 Million USD | 0.25% |
| 2016 | -48.42 Million USD | -17.04% |
| 2015 | -41.85 Million USD | -41.26% |
| 2014 | -29.97 Million USD | -56.29% |
| 2013 | -19.62 Million USD | -42.92% |
| 2012 | -13.73 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -12.6 Million USD | -34.99% |
| 2024 Q2 | -9.57 Million USD | 31.47% |
| 2023 Q1 | -14.11 Million USD | -44.96% |
| 2023 Q4 | -9.24 Million USD | 32.06% |
| 2023 Q3 | -13.6 Million USD | -6.7% |
| 2023 Q2 | -12.75 Million USD | 9.64% |
| 2023 FY | - USD | 16.54% |
| 2022 Q2 | -14.46 Million USD | -1.36% |
| 2022 Q4 | -9.73 Million USD | 36.07% |
| 2022 FY | - USD | -30.05% |
| 2022 Q1 | -14.27 Million USD | -40.08% |
| 2022 Q3 | -15.22 Million USD | -5.26% |
| 2021 Q1 | -9.64 Million USD | -16.08% |
| 2021 Q4 | -10.19 Million USD | 12.32% |
| 2021 Q3 | -11.62 Million USD | -14.09% |
| 2021 FY | - USD | -3.3% |
| 2021 Q2 | -10.18 Million USD | -5.6% |
| 2020 FY | - USD | 20.06% |
| 2020 Q1 | -13.53 Million USD | -9.56% |
| 2020 Q2 | -8.83 Million USD | 34.74% |
| 2020 Q3 | -10.6 Million USD | -20.13% |
| 2020 Q4 | -8.31 Million USD | 21.66% |
| 2019 Q3 | -11.4 Million USD | 16.43% |
| 2019 FY | - USD | -16.16% |
| 2019 Q4 | -12.35 Million USD | -8.29% |
| 2019 Q2 | -13.64 Million USD | -2.11% |
| 2019 Q1 | -13.36 Million USD | -4.5% |
| 2018 Q3 | -8.29 Million USD | 18.88% |
| 2018 FY | - USD | 12.08% |
| 2018 Q1 | -10.71 Million USD | 20.91% |
| 2018 Q2 | -10.22 Million USD | 4.6% |
| 2018 Q4 | -12.79 Million USD | -54.23% |
| 2017 FY | - USD | 0.25% |
| 2017 Q1 | -12.37 Million USD | 3.85% |
| 2017 Q2 | -13.06 Million USD | -5.59% |
| 2017 Q3 | -12.35 Million USD | 5.4% |
| 2017 Q4 | -13.54 Million USD | -9.64% |
| 2016 Q1 | -12.69 Million USD | -10.17% |
| 2016 Q4 | -12.86 Million USD | -8.06% |
| 2016 Q3 | -11.9 Million USD | 10.07% |
| 2016 Q2 | -13.24 Million USD | -4.33% |
| 2016 FY | - USD | -17.04% |
| 2015 Q4 | -11.51 Million USD | -7.01% |
| 2015 Q2 | -10.51 Million USD | -3.71% |
| 2015 Q1 | -10.14 Million USD | -14.92% |
| 2015 FY | - USD | -41.26% |
| 2015 Q3 | -10.76 Million USD | -2.34% |
| 2014 Q1 | -6.69 Million USD | -9.08% |
| 2014 Q3 | -7.62 Million USD | -7.91% |
| 2014 Q4 | -8.82 Million USD | -15.71% |
| 2014 FY | - USD | -56.29% |
| 2014 Q2 | -7.06 Million USD | -5.65% |
| 2013 Q4 | -6.13 Million USD | -39.77% |
| 2013 FY | - USD | -42.92% |
| 2013 Q1 | -4.33 Million USD | 0.0% |
| 2013 Q2 | -4.76 Million USD | -9.85% |
| 2013 Q3 | -4.38 Million USD | 7.89% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 79.46% |
| Prenetics Global Limited | -47.89 Million USD | 8.395% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -2500.771% |
| CareDx, Inc | -89.65 Million USD | 51.063% |
| Exact Sciences Corporation | 41.87 Million USD | 204.774% |
| Exagen Inc. | -19.15 Million USD | -129.076% |
| Inotiv, Inc. | -26.5 Million USD | -65.529% |
| Guardant Health, Inc. | -433.3 Million USD | 89.874% |
| Biodesix, Inc. | -37.1 Million USD | -18.252% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -1665.479% |
| Precipio, Inc. | -4.31 Million USD | -916.095% |
| iSpecimen Inc. | -9.1 Million USD | -381.946% |
| Natera, Inc. | -383.27 Million USD | 88.553% |
| Aspira Women's Health Inc. | -16.49 Million USD | -166.054% |
| Standard BioTools Inc. | -54.45 Million USD | 19.432% |
| 23andMe Holding Co. | -291.87 Million USD | 84.968% |
| Castle Biosciences, Inc. | -45.02 Million USD | 2.552% |
| Personalis, Inc. | -96.8 Million USD | 54.678% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 62.68% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -357.458% |
| OpGen, Inc. | -29.51 Million USD | -48.673% |
| Myriad Genetics, Inc. | -67.8 Million USD | 35.288% |
| ICON Public Limited Company | 1.63 Billion USD | 102.689% |
| NeoGenomics, Inc. | -17.6 Million USD | -149.191% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -2500.771% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 103.603% |
| RadNet, Inc. | 292.78 Million USD | 114.985% |
| MDxHealth SA | -30.46 Million USD | -44.004% |
| Psychemedics Corporation | -251 Thousand USD | -17380.08% |
| Illumina, Inc. | -608 Million USD | 92.784% |
| Check-Cap Ltd. | -17.64 Million USD | -148.598% |
| Twist Bioscience Corporation | -176.7 Million USD | 75.17% |
| DarioHealth Corp. | -53.49 Million USD | 17.981% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 5.751% |
| Sera Prognostics, Inc. | -35.28 Million USD | -24.338% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -348.399% |
| OPKO Health, Inc. | -65.51 Million USD | 33.032% |
| Medpace Holdings, Inc. | 363.15 Million USD | 112.082% |
| Neogen Corporation | 182.59 Million USD | 124.028% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -397.974% |
| Prenetics Global Limited | -47.89 Million USD | 8.395% |
| Mainz Biomed B.V. | -25.01 Million USD | -75.421% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -475.085% |
| Trinity Biotech plc | -24.09 Million USD | -82.069% |
| Neuronetics, Inc. | -22.75 Million USD | -92.781% |
| Sotera Health Company | 514.14 Million USD | 108.534% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -475.085% |